A Phase II Randomized Clinical Trial of Intravitreal Bevacizumab for Diabetic Macular Edema

• Published in: Ophthalmology (Rochester, Minn.) Vol. 114; no. 10; pp. 1860 - 1867.e7
• Main Authors: Scott, Ingrid U, Edwards, Allison R, Beck, Roy W, Bressler, Neil M, Chan, Clement K, Elman, Michael J, Friedman, Scott M, Greven, Craig Michael, Maturi, Raj K, Pieramici, Dante J, Shami, Michel, Singerman, Lawrence J, Stockdale, Cynthia R
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01.10.2007; Elsevier
• Subjects: Aged; Angiogenesis Inhibitors - adverse effects; Angiogenesis Inhibitors - therapeutic use; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized; Bevacizumab; Biological and medical sciences; Combined Modality Therapy; Diabetes. Impaired glucose tolerance; Diabetic Retinopathy - diagnosis; Diabetic Retinopathy - drug therapy; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Etiopathogenesis. Screening. Investigations. Target tissue resistance; Female; Humans; Injections; Laser Coagulation; Macular Edema - diagnosis; Macular Edema - drug therapy; Male; Medical sciences; Middle Aged; Miscellaneous; Ophthalmology; Pilot Projects; Retina - drug effects; Retina - pathology; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A - antagonists & inhibitors; Visual Acuity - drug effects; Vitreous Body; Endocrinopathy; Macula; Edema; Randomization; Diabetes mellitus; Phase II trial; Vitreous body; Ophthalmology
• DOI: 10.1016/j.ophtha.2007.05.062
• ISSN: 0161-6420; 1549-4713

To provide data on the short-term effect of intravitreal bevacizumab for diabetic macular edema (DME). Randomized phase II clinical trial. One hundred twenty-one eyes of 121 subjects (109 eligible for analysis) with DME and Snellen acuity equivalent ranging from 20/32 to 20/320. Random assignment to 1 of 5 groups: (A) focal photocoagulation at baseline (n = 19), (B) intravitreal injection of 1.25 mg of bevacizumab at baseline and 6 weeks (n = 22), (C) intravitreal injection of 2.5 mg of bevacizumab at baseline and 6 weeks (n = 24), (D) intravitreal injection of 1.25 mg of bevacizumab at baseline and sham injection at 6 weeks (n = 22), or (E) intravitreal injection of 1.25 mg of bevacizumab at baseline and 6 weeks with photocoagulation at 3 weeks (n = 22). Central subfield thickness (CST) on optical coherence tomography and best-corrected visual acuity (VA) were measured at baseline and after 3, 6, 9, 12, 18, and 24 weeks. At baseline, median CST was 411 μm and median Snellen VA equivalent was 20/50. Compared with group A, groups B and C had a greater reduction in CST at 3 weeks and about 1 line better median VA over 12 weeks. There were no meaningful differences between groups B and C in CST reduction or VA improvement. A CST reduction > 11% (reliability limit) was present at 3 weeks in 36 of 84 (43%) bevacizumab-treated eyes and 5 of 18 (28%) eyes treated with laser alone, and at 6 weeks in 31 of 84 (37%) and 9 of 18 (50%) eyes, respectively. Combining focal photocoagulation with bevacizumab resulted in no apparent short-term benefit or adverse outcomes. Endophthalmitis developed in 1 eye. The following events occurred during the first 24 weeks in subjects treated with bevacizumab without attributing cause to the drug: myocardial infarction (n = 2), congestive heart failure (n = 1), elevated blood pressure (n = 3), and worsened renal function (n = 3). These results demonstrate that intravitreal bevacizumab can reduce DME in some eyes, but the study was not designed to determine whether treatment is beneficial. A phase III trial would be needed for that purpose.